Sanofi discontinued clinical development of amlitelimab for moderate-to-severe atopic dermatitis. The company will not seek global regulatory approval for the investigational antibody.
A strategic pipeline review concluded the drug offers no meaningful improvement over current standards of care. The decision follows positive late-stage trial results, including sustained clinical responses in long-term studies.
Sanofi is winding down all ongoing atopic dermatitis studies for the drug. A Phase 2 study for celiac disease remains active, with results expected in the second half of 2026.